NovoCure News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

24.05.16	EXEL Rises On Trial Data, XNPT Agrees To Be Acquired, NVO Faces FDA Panel Today (RTTNews)
23.05.16	Novocure Enrolls Last Patient in PANOVA Trial of Tumor Treating Fields Plus Chemotherapy in Advanced Pancreatic Cancer (Businesswire)
19.05.16	Novocure Enrolls Last Patient in INNOVATE Trial Testing Tumor Treating Fields Plus Paclitaxel in Recurrent Ovarian Cancer (Businesswire)
18.05.16	Novocure Announces Presentation of Subgroup Analysis of PANOVA Data Showing Overall Survival Benefit of Tumor Treating Fields Plus Gemcitabine in Advanced Pancreatic Cancer Patients (Businesswire)
13.05.16	Novocure to Present New Preclinical Data Showing Additive Efficacy of Tumor Treating Fields and PD-1 Inhibitors at the American Association of Immunologists’ Annual Meeting 2016 (Businesswire)
11.05.16	Novocure Enters into Employment Agreement with William Doyle (Businesswire)
09.05.16	Novocure Reports First Quarter 2016 Financial Results and Provides Company Update (Businesswire)
06.05.16	Novocure Kicks Off Brain Tumor Awareness Month with New Activities to Support and Inspire Those Affected by Glioblastoma (Businesswire)
05.05.16	Novocure Delivers New Informational Resource for Glioblastoma Brain Cancer (Businesswire)
04.05.16	Blue Cross Blue Shield of Michigan Issues Positive Coverage Decision for Optune (Businesswire)
26.04.16	Novocure’s Optune Now Available at More Than 360 Cancer Treatment Centers in the U.S. (Businesswire)
25.04.16	FDA Approves Investigational Device Exemption for RTOG Trial of Novocure’s Optune together with Bevacizumab for Patients with Bevacizumab-Refractory Recurrent Glioblastoma (Businesswire)
07.04.16	Novocure to Present New Preclinical Data on Tumor Treating Fields at American Association for Cancer Research Annual Meeting 2016 (Businesswire)
05.04.16	Novocure to Report First Quarter 2016 Financial Results (Businesswire)
04.04.16	Novocure und führendes Krebs-Zentrum leiten präklinische Forschungskooperation zur Untersuchung von TTFields ein (Businesswire)
09.03.16	Red Journal Publishes Data Supporting Personalized Treatment Planning to Increase TTFields Efficacy for Patients with Glioblastoma (Businesswire)
03.03.16	Humana Issues Positive Coverage Decision For Optune (Businesswire)
29.02.16	Novocure Reports 2015 Operating Statistics and Financial Results (Businesswire)
23.02.16	Novocure to Present at Cowen and Company 36th Annual Health Care Conference (Businesswire)
15.02.16	Ergebnisse der Phase-3-Studie von Novocure beim neu diagnostizierten Glioblastom erscheinen im ASCO-Bericht 2016 zu Fortschritten in der Krebsmedizin (Businesswire)
12.02.16	Anthem Inc. Issues Positive Coverage Decision For Optune in Newly Diagnosed Glioblastoma (Businesswire)
08.02.16	Novocure’s Phase 3 Pivotal Trial Results in Newly Diagnosed Glioblastoma Selected For ASCO’s Clinical Cancer Advances 2016 Report (Businesswire)
01.02.16	Novocure to Report Fourth Quarter, Year-End Financial Results (Businesswire)
11.01.16	Novocure Announces Preliminary 2015 Operating Statistics (Businesswire)
07.01.16	Novocure Submits PMA Partial Amendment Application to Japanese Pharmaceuticals and Medical Devices Agency for Treatment of Newly Diagnosed Glioblastoma Patients (Businesswire)
06.01.16	Novocure Files Premarket Approval Supplement Application With FDA for Second Generation Optune System (Businesswire)
04.01.16	Novocure to Participate in 34th Annual J.P. Morgan Healthcare Conference (Businesswire)
15.12.15	Novocure to Hold Webcast to Discuss JAMA Publication of EF-14 Phase 3 Clinical Trial Data (Businesswire)
15.12.15	Journal of the American Medical Association (JAMA) veröffentlicht Daten aus zulassungsrelevanter Phase-3-Studie zu Optune plus Temozolomid bei der Behandlung von neu diagnostiziertem Glioblastom (Businesswire)
15.12.15	Journal of the American Medical Association (JAMA) Publishes Pivotal Phase 3 Data for Optune Plus Temozolomide to Treat Newly Diagnosed Glioblastoma (Businesswire)
14.12.15	New Data on Tumor Treating Fields’ Anti-Mitotic Mechanism of Action Published in Scientific Reports (Businesswire)
03.12.15	Retrospective Analysis Shows Optune Safe in Glioblastoma Patients with Implanted Non-Programmable Shunts (Businesswire)
03.12.15	Vorläufige Daten aus Phase-2-Studie belegen Sicherheit der TTFields-Therapie bei Patienten mit Hirnmetastasen, bedingt durch nicht-kleinzelliges Lungenkarzinom (Businesswire)
02.12.15	Preliminary Phase 2 Data Demonstrate Tumor Treating Fields is Safe in Patients with Brain Metastases Originating from Non-Small Cell Lung Cancer (Businesswire)
20.11.15	New Phase 3 Data show Optune in Combination with Second Line Chemotherapy is Superior to Second Line Chemotherapy Alone in Glioblastoma Patients at First Recurrence (Businesswire)
19.11.15	Novocure kündigt 18 Präsentationen zur TTFields-Therapie auf dem SNO-Kongress 2015 an, darunter neue Analysen von Daten der EF-14 Studie bei neu diagnostiziertem Glioblastom (Businesswire)
17.11.15	Novocure Announces Webcast to Discuss New EF-14 Clinical Trial Analyses and Tumor Treating Fields Presentations from SNO 2015 (Businesswire)
17.11.15	Novocure Announces 18 Presentations on Tumor Treating Fields at SNO 2015 Including New Analyses of the EF-14 Newly Diagnosed Glioblastoma Clinical Trial Data (Businesswire)
26.10.15	Novocure Reports Third Quarter 2015 Operating and Financial Results (Businesswire)
19.10.15	NovoCure Limited Announces Closing of Partial Exercise of IPO Over-Allotment Option (Businesswire)
16.10.15	Novocure to Offer On Demand Optune Certification Training for the Radiation Oncology Community at ASTRO 2015 (Businesswire)
16.10.15	Novocure to Report Third Quarter 2015 Financial Results on Monday, October 26 (Businesswire)
07.10.15	NovoCure Limited Announces Closing of Initial Public Offering (Businesswire)
06.10.15	FDA erteilt Zulassung für Optune in Kombination mit Temozolomid für die Behandlung von neu diagnostizierten Glioblastomen (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Lonza Grp	548.20	4.94 %	K V
CieFinRichemont	135.60	1.46 %	K V
UBS Group	28.62	1.13 %	K V
Holcim	90.18	1.08 %	K V
Alcon	76.56	0.63 %	K V
Swiss Re	127.80	-0.31 %	K V
Sika	230.60	-0.60 %	K V
Swiss Life Hldg	687.20	-0.66 %	K V
Part Grp Hldg	1’284.50	-0.96 %	K V
Kuehne+Nagel Int	205.00	-2.80 %	K V

Nachrichten zu NovoCure Limited

Aktien Top/Flop

Meistgelesene Nachrichten